Format

Send to

Choose Destination
J Aerosol Med Pulm Drug Deliv. 2017 Aug;30(4):223-229. doi: 10.1089/jamp.2016.1333. Epub 2017 Feb 3.

A Trans-Nasal Aerosol Delivery Device for Efficient Pulmonary Deposition.

Author information

1
1 University of North Carolina at Chapel Hill , Chapel Hill, North Carolina, Marsico Lung Institute.
2
2 Parion Sciences, Inc. , Durham, North Carolina.

Abstract

BACKGROUND:

Efficient delivery of aerosols to the lungs via the nasal route has been difficult to achieve, but it may offer benefits over the traditional oral route for a range of patient populations. Because slow, continuous delivery of short-acting agents could improve safety, tolerability, compliance, and efficacy when compared with the rapid, intermittent aerosol treatments delivered by mouthpiece or mask, a novel trans-nasal pulmonary aerosol delivery (tPAD) device was developed. The tPAD incorporates an aerosol particle-size selection chamber and a custom nasal cannula that are specifically optimized for aerosol delivery to the lung via the nasal route. The tPAD device produced a steady aerosol output (∼2 mL/h) from an optimized nasal cannula with negligible rainout in the cannula for up to 8 hours. The generated aerosol particles were small enough to minimize nasal deposition [volume median diameter (VMD) = 1.4 μm].

METHODS:

In this proof-of-concept study, gamma scintigraphy was used to quantitate deposition efficiency of 99mTc-labeled DTPA in 7% NaCl (hypertonic saline) in healthy human subjects (n = 6) during a short dosing period (15 minutes). A comparison was made with a standard oral jet nebulizer in the same subjects.

RESULTS:

The tPAD device achieved high pulmonary deposition (39% ± 8%), based on emitted dose, and matched that of the oral jet nebulizer (36% ± 9%). Low fractions of aerosol deposition in the head and nose region were observed for tPAD (6% ± 6%) and jet nebulizer deliver (1% ± 1%) as well.

CONCLUSIONS:

A profile of high pulmonary deposition efficiency and low nasal dose may enable the sustained use of the tPAD platform with a variety of therapeutic agents for a range of pulmonary disorders.

KEYWORDS:

aerosol deposition; hypertonic saline; nasal delivery

PMID:
28157412
PMCID:
PMC5564034
DOI:
10.1089/jamp.2016.1333
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center